Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report report published on Friday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

RVNC has been the subject of a number of other reports. Mizuho reduced their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday, December 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Barclays reiterated an “equal weight” rating and set a $7.00 target price (down from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Finally, HC Wainwright restated a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $8.96.

Revance Therapeutics Stock Up 0.7 %

Shares of NASDAQ RVNC opened at $3.09 on Friday. The firm has a market cap of $322.57 million, a P/E ratio of -1.60 and a beta of 0.81. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $9.74. The company has a 50 day moving average of $4.34 and a 200 day moving average of $4.49.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $67.73 million. As a group, equities analysts expect that Revance Therapeutics will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Revance Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of RVNC. Arizona State Retirement System increased its holdings in Revance Therapeutics by 27.6% in the 2nd quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 5,996 shares in the last quarter. Sei Investments Co. boosted its position in shares of Revance Therapeutics by 52.5% in the second quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 7,628 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Revance Therapeutics by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 20,161 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 7,890 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Revance Therapeutics by 29.4% in the second quarter. The Manufacturers Life Insurance Company now owns 42,296 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 9,601 shares in the last quarter. Finally, Certuity LLC bought a new stake in shares of Revance Therapeutics during the 2nd quarter valued at $26,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.